Component information

Different name of ingredient

• Immunoglobulin G1, anti-(human respiratory syncytial virus fusion protein)(human monoclonal MEDI8897 γ1-chain), disulfide with monoclonal MEDI8897 κ-chain, dimer
• Immunoglobulin G1-kappa, anti-(human respiratory syncytial virus fusion glycoprotein F0 (protein F)); human monoclonal antibody; γ1 heavy chain (1-456) [human VH (Homo sapiens IGHV1-69*01—(IGHD)-IGHJ4*01 (90.1%)) [8.8.19] (1-126) -Homo sapiens IGHG1*03 {CH2 M22>Y(261),S24>T(263),T26>E(265)} (127-456)] (229-214 )-disulfide with kappa light chain (1 -214 ) [human V-KAPPA (Homo sapiens IGKV1-33*01—IGKJ4*01)(96%) [6.3.9] (1 -107 ) -Homo sapiens IGKC*01 (108 -214 )], dimer (235-235 :238-238 )-bisdi
• MEDI-8897 (Medimmune)
• Immunoglobulin G1-kappa, anti-[human respiratory virus (RSV) fusion glycoprotein F], monoclonal antibody; gamma1 heavy chain (1-456) [VH (Homo sapiens IGHV1-69*01(82.5%)-(IGHD)-IGHJ4*01 (93.3%)) [8.8.19] (1-126)-Homo sapiens IGHG1*03, G1m3, nG1m1 (CH1 R120 (223) (127-224), hinge (225-239), CH2 M15.1>Y (261), S16>T (263), T18>E(265) (240-349), CH3 E12 (365), M14 (367) (350-454), CHS (455-456)) (127-456)], (229-214 )-disulfide with kappa light chain (1 -214 ) [V-KAPPA (Homo sapiens IGKV1-33*01 (93
• Nirsevimabum
• SP 0232
• Nirsevimab

Alternative medicine with selected ingredient